Jay C Horrow1,2, Manfred Blobner3,4, Wen Li1, John Lombard1, Marcel Speek1, Matthew DeAngelis1, W Joseph Herring5. 1. Department of Clinical Research, Merck & Co., Inc., 2000 Galloping Hill Rd, UG-4C-13, Kenilworth, NJ, 07033, USA. 2. Present address: Anesthesiology & Critical Care Medicine, University of Pennsylvania, Philadelphia, PA, USA. 3. Department of Anaesthesiology and Intensive Care Medicine, School of Medicine, Technical University of Munich, Munich, Germany. 4. Department of Anaesthesiology and Intensive Care Medicine, Faculty of Medicine, University of Ulm, Munich, Germany. 5. Department of Clinical Research, Merck & Co., Inc., 2000 Galloping Hill Rd, UG-4C-13, Kenilworth, NJ, 07033, USA. william_herring@merck.com.
Abstract
BACKGROUND: This randomized, double-blind trial evaluated sugammadex-mediated recovery time from rocuronium- or vecuronium-induced moderate (M-) or deep (D-) neuromuscular block in morbidly obese adults dosed by actual (ABW) or ideal body weight (IBW). METHODS: Adults with BMI ≥40 kg/m2 were randomized to 1 of 5 groups: M-neuromuscular block, sugammadex 2 mg/kg ABW; M-neuromuscular block, sugammadex 2 mg/kg IBW; M-neuromuscular block, neostigmine 5 mg, and glycopyrrolate 1 mg; D-neuromuscular block, sugammadex 4 mg/kg ABW; or D-neuromuscular block, sugammadex 4 mg/kg IBW. Supramaximal train of four (TOF) stimulation of the ulnar nerve (TOF-watch SX®) monitored recovery. Primary endpoint was time to TOF ratio ≥ 0.9 for ABW and IBW groups pooled across neuromuscular blocking agent (NMBA)/blocking depth, analyzed by log-rank test stratified for agent and depth. Prespecified safety outcomes included treatment-emergent bradycardia, tachycardia, and other arrhythmias, and adjudicated hypersensitivity and anaphylaxis. RESULTS: Of 207 patients randomized, 188 received treatment (28% male, BMI 47 ± 5.1 kg/m2, age 48 ± 13 years). Recovery was 1.5 min faster with ABW vs IBW dosing. The sugammadex 2 mg/kg groups recovered 9-fold faster [time 0.11-fold, 95% CI 0.08 to 0.14] than the neostigmine group. ABW (5.3%) and IBW (2.7%) groups had similar incidences of recovery time > 10 min (95% CI of difference: - 4.8 to 11.0%); 84% for neostigmine group. Re-curarization occurred in one patient each in the 2 mg/kg IBW and neostigmine groups. Prespecified safety outcomes occurred with similar incidences. CONCLUSIONS: ABW-based sugammadex dosing yields faster reversal without re-curarization, supporting ABW-based sugammadex dosing in the morbidly obese, irrespective of the depth of neuromuscular block or NMBA used. TRIAL REGISTRATION: Registered on November 17, 2017, at ClinicalTrials.gov under number NCT03346070 .
BACKGROUND: This randomized, double-blind trial evaluated sugammadex-mediated recovery time from rocuronium- or vecuronium-induced moderate (M-) or deep (D-) neuromuscular block in morbidly obese adults dosed by actual (ABW) or ideal body weight (IBW). METHODS: Adults with BMI ≥40 kg/m2 were randomized to 1 of 5 groups: M-neuromuscular block, sugammadex 2 mg/kg ABW; M-neuromuscular block, sugammadex 2 mg/kg IBW; M-neuromuscular block, neostigmine 5 mg, and glycopyrrolate 1 mg; D-neuromuscular block, sugammadex 4 mg/kg ABW; or D-neuromuscular block, sugammadex 4 mg/kg IBW. Supramaximal train of four (TOF) stimulation of the ulnar nerve (TOF-watch SX®) monitored recovery. Primary endpoint was time to TOF ratio ≥ 0.9 for ABW and IBW groups pooled across neuromuscular blocking agent (NMBA)/blocking depth, analyzed by log-rank test stratified for agent and depth. Prespecified safety outcomes included treatment-emergent bradycardia, tachycardia, and other arrhythmias, and adjudicated hypersensitivity and anaphylaxis. RESULTS: Of 207 patients randomized, 188 received treatment (28% male, BMI 47 ± 5.1 kg/m2, age 48 ± 13 years). Recovery was 1.5 min faster with ABW vs IBW dosing. The sugammadex 2 mg/kg groups recovered 9-fold faster [time 0.11-fold, 95% CI 0.08 to 0.14] than the neostigmine group. ABW (5.3%) and IBW (2.7%) groups had similar incidences of recovery time > 10 min (95% CI of difference: - 4.8 to 11.0%); 84% for neostigmine group. Re-curarization occurred in one patient each in the 2 mg/kg IBW and neostigmine groups. Prespecified safety outcomes occurred with similar incidences. CONCLUSIONS: ABW-based sugammadex dosing yields faster reversal without re-curarization, supporting ABW-based sugammadex dosing in the morbidly obese, irrespective of the depth of neuromuscular block or NMBA used. TRIAL REGISTRATION: Registered on November 17, 2017, at ClinicalTrials.gov under number NCT03346070 .
Authors: Sam Baete; Gerd Vercruysse; Margot Vander Laenen; Pieter De Vooght; Jeroen Van Melkebeek; Dimitri Dylst; Maud Beran; Jan Van Zundert; René Heylen; Willem Boer; Sam Van Boxstael; Tom Fret; Hans Verhelst; Cathy De Deyne; Frank Jans; Pascal Vanelderen Journal: Anesth Analg Date: 2017-05 Impact factor: 5.108
Authors: Manfred Blobner; Jennifer M Hunter; Claude Meistelman; Andreas Hoeft; Markus W Hollmann; Eva Kirmeier; Heidrun Lewald; Kurt Ulm Journal: Br J Anaesth Date: 2019-10-10 Impact factor: 9.166
Authors: Hendrikus Jm Lemmens; Mohammad I El-Orbany; James Berry; Jovino Ben Morte; Gavin Martin Journal: BMC Anesthesiol Date: 2010-09-01 Impact factor: 2.217
Authors: David M Broussard; Manfred Blobner; W Joseph Herring; Yuki Mukai; Aobo Wang; Jeannine Lutkiewicz; John F Lombard; Li Lin; Molly Watkins Journal: BMC Anesthesiol Date: 2021-10-28 Impact factor: 2.217